Agenus Inc (AGEN) Stock Analysis
Verdict: AVOID
Severe liquidity distress ($3.0M cash vs -$158.9M FCF) forces immediate dilution risk, overriding immuno-oncology clinical potential.
Investment score: 27/100
Analysis as of
Is Agenus Inc stock worth reviewing? AI model thesis
The AI model evaluates Agenus as a high-risk biotechnology stock where extreme liquidity depletion ($3.00M cash vs -$158.89M FCF burn) threatens equity holders with severe dilution.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Agenus Inc opportunities and risks
What speaks for AGEN
- Immuno-Oncology Pipeline Validation
What speaks against AGEN
- Immediate Insolvency and Equity Dilution Risk
Frequently asked questions about Agenus Inc (AGEN)
Is AGEN stock a good investment?
The cached TradeMates AI model rates Agenus Inc as AVOID with an investment score of 27/100. The AI model evaluates Agenus as a high-risk biotechnology stock where extreme liquidity depletion ($3.00M cash vs -$158.89M FCF burn) threatens equity holders with severe dilution. This is algorithmic model output, not personal investment advice.
Is AGEN stock a buy?
The TradeMates model verdict for AGEN is AVOID with an investment score of 27/100. Treat this as a model signal to review, not a personal buy recommendation.